The Czech Republic could become the second EU country after France to cover GLP-1 obesity drugs for children with severe obesity, following an announcement at the opening of Novo Nordisk's new €320 million factory in Central Bohemia. Should public health insurance pay for these medications?

Yes for children who meet strict medical criteria. 14 %
Only after other treatments (diet, exercise, counseling) have been tried. 62 %
Public health insurance shouldn't pay for these drugs. 10 %
Not sure, I need more evidence about the long-term benefits and risks. 14 %
208 readers voted on this poll. Voting is open